Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 16.09.2024 1 Am J Clin Oncol 4 BMC Cancer 1 Cancer Cell 5 Cancer Lett 1 Cancer Res 2 Carcinogenesis 4 Clin Lung Cancer 1 Eur J Cardiothorac Surg 5 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Surg Oncol 1 J Thorac Cardiovasc Surg 18 J Thorac Oncol 11 Lung Cancer 1 N Engl J Med 1 Oncogene 1 Oncologist 5 PLoS One 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. QURESHI Z, Altaf F, Jamil A, Siddique R, et al
   Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment.
   Am J Clin Oncol. 2024 Sep 11. doi: 10.1097/COC.0000000000001138.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. HAGHIGHIKIAN SM, Shirinzadeh-Dastgiri A, Ershadi R, Vakili-Ojarood M, et al
   Correlation of TNF-alpha polymorphisms with susceptibility to lung cancer: evidence from a meta-analysis based on 29 studies.
   BMC Cancer. 2024;24:1113.
   PubMed         Abstract available
   
   
3. RUCO A, Lofters AK, Lu H, Baxter NN, et al
   Lung cancer survival by immigrant status: a population-based retrospective cohort study in Ontario, Canada.
   BMC Cancer. 2024;24:1114.
   PubMed         Abstract available
   
   
4. LIU R, Wang J, Zhang L, Wang S, et al
   GLIDR-mediated regulation of tumor malignancy and cisplatin resistance in non-small cell lung cancer via the miR-342-5p/PPARGC1A axis.
   BMC Cancer. 2024;24:1126.
   PubMed         Abstract available
   
   
5. CUI J, An Z, Zhou X, Zhang X, et al
   Prognosis and risk factor assessment of patients with advanced lung cancer with low socioeconomic status: model development and validation.
   BMC Cancer. 2024;24:1128.
   PubMed         Abstract available
   
   

   
   Cancer Cell

6. XU J, Wan R, Cai Y, Cai S, et al
   Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
   Cancer Cell. 2024;42:1598-1613.
   PubMed         Abstract available
   
   

   
   Cancer Lett

7. HUANG L, Wang J, Wang X, Zheng S, et al
   Sulforaphane suppresses bladder cancer metastasis via blocking actin nucleation-mediated pseudopodia formation.
   Cancer Lett. 2024 Jul 29:217145. doi: 10.1016/j.canlet.2024.217145.
   PubMed         Abstract available
   
   
8. GANG X, Yan J, Li X, Shi S, et al
   Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions.
   Cancer Lett. 2024 Sep 9:217241. doi: 10.1016/j.canlet.2024.217241.
   PubMed         Abstract available
   
   
9. LA VECCHIA S, Fontana S, Salaroglio IC, Anobile DP, et al
   Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy.
   Cancer Lett. 2024;604:217221.
   PubMed         Abstract available
   
   
10. WEI X, Uchibori K, Kondo N, Utsumi T, et al
    MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
    Cancer Lett. 2024 Sep 5:217220. doi: 10.1016/j.canlet.2024.217220.
    PubMed         Abstract available
    
    
11. WU J, Chen Y, Zou H, Xu K, et al
    6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells.
    Cancer Lett. 2024;601:217177.
    PubMed         Abstract available
    
    

    
    Cancer Res

12. SMITH MR, Dixon CB, Wang Y, Liu Y, et al
    Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-type Non-Small Cell Lung Cancer.
    Cancer Res. 2024 Sep 9. doi: 10.1158/0008-5472.CAN-24-0658.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

13. CHIAPPARA G, Di Vincenzo S, Cascio C, Pace E, et al
    Stem cells, Notch-1 signaling, and oxidative stress: a hellish trio in cancer development and progression within the airways. Is there a role for natural compounds?
    Carcinogenesis. 2024;45:621-629.
    PubMed         Abstract available
    
    
14. ZEIDLER-ERDELY PC, Kodali V, Falcone LM, Mercer R, et al
    Absence of lung tumor promotion with reduced tumor size in mice after inhalation of copper welding fumes.
    Carcinogenesis. 2024;45:630-641.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

15. PAN H, Luo Q
    "Video Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Population: A Multicenter Retrospective Cohort Study".
    Clin Lung Cancer. 2024 Aug 17:S1525-7304(24)00179.
    PubMed        
    
    
16. PARK JA, Yalamanchili S, Brown Z, Myers A, et al
    Implementation of an Electronic Medical Record Alert Significantly Increases Lung Cancer Screening Uptake.
    Clin Lung Cancer. 2024 Aug 18:S1525-7304(24)00157.
    PubMed         Abstract available
    
    
17. QASIM R, Riaz Z
    Video Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Population: A Multicenter Retrospective Cohort Study.
    Clin Lung Cancer. 2024 Aug 16:S1525-7304(24)00178.
    PubMed        
    
    
18. BESTVINA CM, Hara JHL, Karrison T, Bowar B, et al
    DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Aug 13:S1525-7304(24)00159.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

19. LEE JO, Lee GD, Choi S, Kim HR, et al
    Surgical prognosis of lung invasive mucinous and non-mucinous adenocarcinoma: propensity score matched analysis.
    Eur J Cardiothorac Surg. 2024;66:ezae316.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. KAMTAM DN, Binkley MS, Kapula N, Sadeghi C, et al
    First in Human Phase 1 Clinical Trial of Stereotactic Irradiation to Achieve Lung Volume Reduction (SILVR) in Severe Emphysema.
    Int J Radiat Oncol Biol Phys. 2024;120:345-356.
    PubMed         Abstract available
    
    
21. SADDOUGHI SA, Kern R
    Stereotactic Irradiation to Achieve Lung Volume Reduction (SILVR) Lining: We Can All Have a Piece of the Pie.
    Int J Radiat Oncol Biol Phys. 2024;120:357-358.
    PubMed        
    
    
22. MCCALL NS, Higgins KA
    Toward the Optimal Delivery of Twice-Daily Thoracic Chemoradiation in Limited-Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2024;120:343-344.
    PubMed        
    
    
23. LI GJ, Tan H, Nusrat H, Chang J, et al
    Safety and Efficacy of Stereotactic Body Radiation Therapy for Ultra-central Thoracic Tumors: A Single Center Retrospective Review.
    Int J Radiat Oncol Biol Phys. 2024;120:359-369.
    PubMed         Abstract available
    
    
24. JABBOUR SK, Higgins KA, Yom SS, Goodman KA, et al
    Recapping Radiation Related Abstracts at ASCO 2024: A Commentary about the Fundamental Role of Radiation Therapy in Esophageal and Lung Cancers.
    Int J Radiat Oncol Biol Phys. 2024;120:309-314.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

25. GU G, Liu C, Zhu X, Yang Y, et al
    Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
    J Cancer Res Clin Oncol. 2024;150:413.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

26. AHN MJ, Tanaka K, Paz-Ares L, Cornelissen R, et al
    Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
    J Clin Oncol. 2024 Sep 9:JCO2401544. doi: 10.1200/JCO-24-01544.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

27. SONG KJ, Faith I, Tuminello S, Taioli E, et al
    Patients With Surgically Resectable Lung Cancer Who Opt for Radiation Have Worse Outcomes.
    J Surg Oncol. 2024 Sep 10. doi: 10.1002/jso.27873.
    PubMed         Abstract available
    
    
28. DEBOEVER N, Eisenberg MA, Antonoff MB, Hofstetter WL, et al
    Relationship of Surgical Approach With Financial Toxicity in Patients With Resected Lung Cancer.
    J Surg Oncol. 2024 Sep 10. doi: 10.1002/jso.27870.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

29. ADACHI H, Ito H, Nagashima T, Isaka T, et al
    Mediastinal lymph node dissection in segmentectomy for peripheral c-stage IA (
    J Thorac Cardiovasc Surg. 2024 Sep 9:S0022-5223(24)00786.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

30. ROMA L, Bubendorf L
    Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
    J Thorac Oncol. 2024;19:e38-e39.
    PubMed        
    
    
31. ZHOU L, Li M, Li W
    Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
    J Thorac Oncol. 2024;19:e37-e38.
    PubMed        
    
    
32. TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al
    Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?".
    J Thorac Oncol. 2024;19:e36.
    PubMed        
    
    
33. NIU Y, Xie J, Li Z
    The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
    J Thorac Oncol. 2024;19:e34-e35.
    PubMed        
    
    
34. HIGASHIYAMA RI, Yoshida T
    A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
    J Thorac Oncol. 2024;19:e33-e34.
    PubMed        
    
    
35. HAN Z, Liu L, Jiang Y
    Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
    J Thorac Oncol. 2024;19:e31-e32.
    PubMed        
    
    
36. ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al
    Lung Cancer in Finland.
    J Thorac Oncol. 2024;19:1265-1271.
    PubMed        
    
    
37. YANG CY, Lee MR, Yang PC
    Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection.
    J Thorac Oncol. 2024;19:1261-1264.
    PubMed        
    
    
38. ROSSI S, Costa R, di Federico A, Lo Bianco F, et al
    Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
    J Thorac Oncol. 2024;19:1352-1355.
    PubMed         Abstract available
    
    
39. LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al
    Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
    J Thorac Oncol. 2024;19:1297-1309.
    PubMed         Abstract available
    
    
40. ROMA L, Ercan C, Conticelli F, Akyurek N, et al
    Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
    J Thorac Oncol. 2024;19:1284-1296.
    PubMed         Abstract available
    
    
41. GILL RR, Nowak AK, Giroux DJ, Eisele M, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1310-1325.
    PubMed         Abstract available
    
    
42. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
    A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
    J Thorac Oncol. 2024;19:e41-e43.
    PubMed        
    
    
43. JIANG Y, Zhang L
    Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e43.
    PubMed        
    
    
44. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
    A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
    J Thorac Oncol. 2024;19:e44-e45.
    PubMed        
    
    
45. HORNE A, Harada K, Brown KD, Lee Min Chua K, et al
    Erratum to "Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164-1185]".
    J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775.
    PubMed        
    
    
46. CHEN H, Yang S, Wang L, Wu Y, et al
    High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study.
    J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269.
    PubMed         Abstract available
    
    
47. NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al
    Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265.
    PubMed         Abstract available
    
    

    
    Lung Cancer

48. MARKS JA, Gandhi N, Halmos B, Marmarelis ME, et al
    Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
    Lung Cancer. 2024;196:107935.
    PubMed         Abstract available
    
    
49. LIAO D, Long M, Zhang J, Wei X, et al
    Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.
    Lung Cancer. 2024;196:107936.
    PubMed         Abstract available
    
    
50. MANSFIELD AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, et al
    Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
    Lung Cancer. 2024;195:107928.
    PubMed         Abstract available
    
    
51. LIU KJ, Li HR, Tan QQ, Jiang T, et al
    Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
    Lung Cancer. 2024;195:107933.
    PubMed         Abstract available
    
    
52. NASO J, Desai A, Smith CJ, Ashara YP, et al
    Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.
    Lung Cancer. 2024;195:107927.
    PubMed         Abstract available
    
    
53. WEI Y, Wu R, Yang S, Cao Y, et al
    MiR-137 mediated high expression of TIGD1 promotes migration, invasion, and suppresses apoptosis of lung adenocarcinoma.
    Lung Cancer. 2024;195:107918.
    PubMed         Abstract available
    
    
54. LI Y, Xie F, Zheng Q, Zhang Y, et al
    Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
    Lung Cancer. 2024;195:107930.
    PubMed         Abstract available
    
    
55. YING L, Lu T, Tian Y, Guo H, et al
    A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel.
    Lung Cancer. 2024;195:107902.
    PubMed         Abstract available
    
    
56. ALIREZAIE N, Chong AL, Kommoss FKF, Sabbaghian N, et al
    Exomic and epigenomic analysis of pulmonary blastoma.
    Lung Cancer. 2024;195:107916.
    PubMed         Abstract available
    
    
57. OTTE N, Fraune E, Cetiner Y, Felten MK, et al
    Asbestos Surveillance Program Aachen (ASPA): Cancer mortality among asbestos exposed power industry workers.
    Lung Cancer. 2024;195:107899.
    PubMed         Abstract available
    
    
58. LU S, Zhang Y, Zhang G, Zhou J, et al
    Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
    Lung Cancer. 2024;195:107901.
    PubMed         Abstract available
    
    

    
    N Engl J Med

59. WITTROCK E, Hagner MD
    Cannonball Pulmonary Lesions.
    N Engl J Med. 2024;391:844.
    PubMed        
    
    

    
    Oncogene

60. LAILLER C, Didelot A, Garinet S, Berthou H, et al
    PrP(C) controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.
    Oncogene. 2024;43:2781-2794.
    PubMed         Abstract available
    
    

    
    Oncologist

61. ALVES DE SOUZA G, Dornellas DMS, Campregher PV, Teixeira CHA, et al
    Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
    Oncologist. 2024;29:764-767.
    PubMed         Abstract available
    
    

    
    PLoS One

62. 
    Correction: The efficacy of machine learning models in lung cancer risk prediction with explainability.
    PLoS One. 2024;19:e0310604.
    PubMed         Abstract available
    
    
63. PIRES DC, Arueira Chaves L, Dantas Cardoso CH, Faria LV, et al
    Effects of low dose computed tomography (LDCT) on lung cancer screening on incidence and mortality in regions with high tuberculosis prevalence: A systematic review.
    PLoS One. 2024;19:e0308106.
    PubMed         Abstract available
    
    
64. WU X, Li W, Chen Y
    Differences in the risk association of TERT-CLPTM1L rs4975616 (A>G) with lung cancer between Caucasian and Asian populations: A meta-analysis.
    PLoS One. 2024;19:e0309747.
    PubMed         Abstract available
    
    
65. FANIZZI A, Fadda F, Maddalo M, Saponaro S, et al
    Developing an ensemble machine learning study: Insights from a multi-center proof-of-concept study.
    PLoS One. 2024;19:e0303217.
    PubMed         Abstract available
    
    
66. GEUBBELMANS M, Claes J, Nijsten K, Gervois P, et al
    Optimization of whole slide imaging scan settings for computer vision using human lung cancer tissue.
    PLoS One. 2024;19:e0309740.
    PubMed         Abstract available
    
    

    
    Thorax

67. GONNELLI F, Kaur J, Bonifazi M, Baldwin D, et al
    Pulmonary fibrosis and lung cancer: an analysis of the Clinical Practice Research Datalink linked to the National Cancer Registration Dataset.
    Thorax. 2024 Sep 10:thorax-2024-221865. doi: 10.1136/thorax-2024-221865.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.